Core Viewpoint - Merck is set to acquire Terns Pharmaceuticals for $6.7 billion, focusing on the development of an oral treatment for leukemia [1] Company Summary - Merck is investing $6.7 billion in Terns Pharmaceuticals, indicating a strong commitment to expanding its oncology portfolio [1] - Terns Pharmaceuticals is currently developing an innovative oral treatment specifically targeting leukemia, which could enhance treatment options in this therapeutic area [1] Industry Summary - The acquisition highlights the growing interest and investment in oncology treatments, particularly in developing oral therapies for blood cancers like leukemia [1] - This move reflects a broader trend in the pharmaceutical industry towards strategic acquisitions to bolster research and development capabilities in high-demand therapeutic areas [1]

Core Insights - Marvel Biosciences Corp. has selected Novotech as the contract research organization for its upcoming Phase I clinical trial of the lead drug candidate MB-204, which targets autism spectrum disorder and related conditions [1][2] - The partnership with Novotech is expected to enhance the efficiency of the Phase I program due to Australia's favorable regulatory environment and significant tax credits [2] Company Overview - Marvel Biosciences Corp. is a Calgary-based biotechnology company focused on developing new treatments for neurological diseases and neurodevelopmental disorders, with its lead drug candidate MB-204 being a novel adenosine A2A antagonist [3] - MB-204 is a fluorinated derivative of Istradefylline, an approved Parkinson's drug, and is being explored for its potential in treating conditions such as autism, depression, and rare disorders like Rett syndrome and Fragile X syndrome [3]

Core Viewpoint - Merck is acquiring Terns Pharmaceuticals for $6.7 billion, marking its third multibillion-dollar acquisition in the past year as it prepares for the patent expiration of its leading cancer drug Keytruda in 2028 [1] Group 1: Acquisition Details - The acquisition price for Terns Pharmaceuticals is $6.7 billion [1] - This acquisition is part of Merck's strategy to strengthen its portfolio ahead of Keytruda's patent loss [1] Group 2: Market Reaction - Following the announcement, Terns shares increased by 5.3% [1] - Merck's stock remained largely unchanged in premarket trading [1]

Core Insights - United Laboratories International Holdings Ltd. and Novo Nordisk A/S have reported positive topline results from a phase 2 trial of UBT251, a triple agonist for type 2 diabetes treatment [1] Group 1: Trial Overview - The phase 2 trial involved once-weekly injectable doses of UBT251 (2 mg, 4 mg, and 6 mg) compared to placebo and Semaglutide 1 mg in Chinese patients with type 2 diabetes [2] - The primary endpoint was the change in HbA1c from baseline after 24 weeks, with baseline averages of HbA1c at 8.12%, body weight at 80.1 kg, and BMI at 29.1 kg/m² [2] Group 2: Efficacy Results - UBT251 achieved a mean reduction in HbA1c of 2.16%, outperforming Semaglutide (1.77%) and placebo (0.66%) [3] - UBT251 also resulted in a body weight reduction of up to 9.8%, compared to 4.8% for Semaglutide and 1.4% for placebo [3] Group 3: Secondary Endpoints and Safety - UBT251 showed improvements over placebo in key secondary endpoints, including waist circumference, blood pressure, and lipid levels [4] - The safety and tolerability profile of UBT251 was consistent with previous clinical trials of triple-G agonists [4] Group 4: Future Development Plans - United Biotechnology plans to initiate two phase 3 trials with UBT251 in Chinese patients with type 2 diabetes [5] - Novo Nordisk intends to start a global phase 2 trial with UBT251 later this year, alongside an ongoing global phase 2 trial in weight management with results expected next year [5] Group 5: Competitive Landscape - Eli Lilly's Retatrutide is noted as the most advanced triple-G agonist, having shown significant reductions in HbA1c and weight in its phase 3 trial for type 2 diabetes [6] - In the TRANSCEND-T2D-1 study, Retatrutide reduced HbA1c by 1.7% to 2.0% and participants on the 12 mg dose lost an average of 36.6 lbs (16.8%) [7]

Group 1: Company Performance and Analyst Ratings - Merck & Co., Inc. (NYSE:MRK) is recognized as one of the 10 Most Profitable S&P 500 Stocks to Buy Now [1] - Citi raised the price target on Merck to $125 from $120 while maintaining a Neutral rating [1][6] - Wells Fargo increased its price target on Merck to $150 from $135 and maintained an Overweight rating, highlighting the potential of Sac-TMT to become "best-in-class" and possibly replace chemotherapy across several indications [4] Group 2: Product Developments - Merck's Animal Health division received FDA approval for an expanded label for Bravecto Quantum in dogs, allowing treatment and control for additional tick species for up to 12 months with a single injection [2] - New data from Merck's cardio-pulmonary pipeline will be presented at the American College of Cardiology meeting, including results from the Phase 3 CORALreef AddOn trial and the Phase 2 CADENCE trial [3]

Core Viewpoint - Merck has announced its acquisition of Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which represents a premium of 31% over the 60-day average stock price and 42% over the 90-day average stock price as of March 24, 2026 [2][3]. Company Overview - Merck, known as MSD outside the U.S. and Canada, is enhancing its oncology portfolio through the acquisition of Terns, which focuses on developing innovative therapies for chronic myeloid leukemia (CML) [2][3]. - Terns Pharmaceuticals is a clinical-stage oncology company with a lead candidate, TERN-701, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor [2][4]. Acquisition Details - The acquisition is subject to Terns' stockholders tendering their shares and regulatory approvals, with an expected closing in the second quarter of 2026 [5]. - The transaction will be accounted for as an asset acquisition, resulting in a charge of approximately $5.8 billion, or about $2.35 per share, impacting both second quarter and full year 2026 financial results [5]. Product Development - TERN-701 is currently in Phase 1/2 development, specifically in the CARDINAL trial for patients with Philadelphia chromosome-positive CML who have experienced treatment failure or intolerance [3][11]. - The FDA granted Orphan Drug Designation for TERN-701 in March 2024, indicating its potential significance in treating CML [3]. Clinical Trial Insights - Early clinical trials of TERN-701 have shown promising results, including encouraging rates of major molecular response and low incidence of severe adverse events [4][11]. - The CARDINAL trial has completed its dose escalation phase with no dose-limiting toxicities observed, and the expansion phase is currently underway [11]. Market Need - There remains a significant need for innovative therapies in CML, as existing treatments may not provide optimal responses for all patients [5][12]. - TERN-701 aims to offer a differentiated option for patients, potentially improving efficacy and safety compared to current treatments [5][10].

Boehringer Ingelheim Pharmaceuticals 2026 Annual Press Conference Summary Company Overview - **Company**: Boehringer Ingelheim Pharmaceuticals - **Date of Conference**: March 25, 2026 - **Key Focus**: Annual results for the year 2025, insights into Human Pharma and Animal Health businesses Key Points Financial Performance - **Net Sales**: Achieved EUR 27.8 billion in 2025, representing a growth of 7.3% compared to the previous year [30] - **Human Pharma Sales**: EUR 22.7 billion with a growth of 7.4% [31] - **Key Products**: - Jardiance: EUR 8.8 billion, growth of 8.7% [31] - Ofev: EUR 3.8 billion, growth of over 5% [31] - **Animal Health Sales**: EUR 4.9 billion with a growth of 6.5% [32] - **Key Products**: - NexGard: EUR 1.4 billion, growth of 8.5% [32] - BULTAVO 3: EUR 75 million, significant due to its role in combating the bluetongue virus [33] Research and Development (R&D) - **R&D Investment**: EUR 6.4 billion, representing 23% of revenues, with Human Pharma at over 27% and Animal Health at almost 11% [37] - **R&D Focus**: - 80 projects in the Human Pharma pipeline across various therapeutic areas [39] - New launches in 2025 included Jascayd for idiopathic pulmonary fibrosis and Hernexeos for HER2 mutant non-small cell lung cancer [12][14] - **Innovation Recognition**: Ranked 9th among the most research-intensive companies in the EU [10] Market Trends and Challenges - **Animal Health Industry**: - Growth driven by increasing pet ownership and investment in animal health [22] - Significant outbreaks of transboundary animal diseases, including avian influenza and foot-and-mouth disease, impacting livestock and communities [23][24] - **Human Health Trends**: - Focus on interconnectedness of diseases, particularly in cardiorenal metabolism [16] - Emphasis on early diagnosis and treatment to prevent severe health complications [17] Future Outlook - **2026 Expectations**: Anticipated growth on a comparable basis, with a strong focus on innovation as a key driver of value [58] - **Pipeline Developments**: - Survodutide for obesity and MASH expected to have pivotal data readouts in 2026 [45] - Expansion into eye health and oncology with multiple new molecules in clinical research [46][47] Strategic Investments - **Infrastructure Investments**: EUR 1.4 billion in capital expenditures across 40 major projects globally [34] - **Technological Advancements**: Investment in AI and digital tools to enhance drug development and patient engagement [49][50] Workforce and Employment - **Global Workforce**: Over 54,000 employees, with a 2% growth in Germany [54] - **Training and Development**: More than EUR 80 million spent on employee training, emphasizing the importance of skill development [52] Conclusion - **Company Position**: Boehringer Ingelheim remains resilient and committed to innovation, with a strong pipeline and strategic investments aimed at addressing both current and future healthcare challenges [38]

"心血管慢病管理，用药是基石。"马长生教授指出，评价心血管慢病长期管理用药，需从"有效性、安全性、依从性、可及性"四个维度综 合考量。 疗效确凿是基石。药品的核心价值在于治疗作用，必须能切实降低患者心梗、卒中、心血管死亡等硬终点事件的风险。 警惕海外购药与"神药"陷阱，五大陷阱要认清 在日常门诊中，马长生教授常遇到一些考虑购买海外原研药、又心存顾虑的患者。他梳理出五大常见认知误区，提醒公众警惕。 误区一：盲目认为"国外的月亮比较圆"。药品是受严格监管的科学产物。同一化学成分，无论是海外原研药，还是通过国家仿制药质量和 疗效一致性评价的国产药，其生物等效性均有严格数据支撑，国产高品质仿制药在疗效和安全性上同样有保障。 作为典型的慢性病，心血管疾病的长期规范管理直接关系到患者的生命安全与生活质量。围绕心血管慢病患者在购药、用药中的常见误区 及科学应对策略，近日，新华网专访了首都医科大学附属北京安贞医院心脏内科中心主任马长生教授。 安全稳定是保障。心血管药物往往需终身服用，不仅要求药物本身毒副作用可控，更要求每一批次药品的质量高度稳定。杂质控制、溶出 行为等工艺上的细微差异，在长期服用背景下都可能被放大。 用药依从 ...

Diplomatic Developments - The United States has proposed a comprehensive 15-point ceasefire plan to Iran, addressing missile limits and nuclear program rollback in exchange for sanctions relief [2][9] - High-level talks between Washington and Tehran regarding the nuclear program may occur in Islamabad soon, as indicated by IAEA Chief Rafael Grossi [3] Energy Market Implications - BlackRock CEO Larry Fink warned that oil prices reaching $150 per barrel could lead to a global economic contraction, emphasizing the importance of stabilizing energy flows through the Strait of Hormuz [4][9] - European equity markets showed positive movement, with Germany's DAX rising 1.5% and the STOXX 600 gaining 0.71% amid hopes for a diplomatic resolution [9] Economic Sentiment in Europe - The German Ifo Business Confidence index is expected to decline due to logistical uncertainties stemming from the conflict [5] - Spain's Producer Price Index (PPI) for February fell 7.0% year-on-year, indicating a reduction in industrial price pressures, while Sweden's Economic Tendency Survey slightly decreased to 99.9, reflecting subdued consumer confidence at 95.2 [8] Central Bank Actions - Traders have shifted expectations for the Bank of England, now pricing in 61 basis points of interest rate hikes by year-end, a significant change from previous cut expectations [6][9] - ECB's Mārtiņš Kazāks suggested that an early rate move may be necessary if inflation spreads across the economy [6] Corporate Developments - Johnson & Johnson is reportedly considering a takeover of Nanobiotix, indicating potential strategic moves in the healthcare sector [7] - COSCO Shipping has resumed booking services in the Middle East, including the UAE, Saudi Arabia, and Iraq, which may signal easing maritime security concerns [9]

Core Insights - The report highlights a strong growth trend in China's high-tech industries, with sales revenue increasing by 16.1% year-on-year in the first two months of the year, particularly driven by high-tech services and manufacturing sectors [2] - The report emphasizes the importance of economic globalization and China's role in providing certainty in a volatile global environment, as stated by the Ministry of Commerce [2] - The smart glasses market in China is projected to see significant growth, with an expected shipment volume of 2.46 million units in 2025, reflecting an 87.1% year-on-year increase [2] - The report outlines a strategic plan for the AI server industry in Shenzhen, aiming for substantial growth in production capacity and market share by 2028 [2] - The machine tool industry in China is showing signs of recovery, with a reported revenue of 288.7 billion yuan in 2025, marking a 10.3% year-on-year increase [5] Industry Summaries High-Tech Industry - High-tech service revenue grew by 17.2%, with significant increases in technology intermediary services and natural scientific research [2] - High-tech manufacturing revenue increased by 14.5%, driven by sectors such as aerospace and consumer electronics [2] Smart Glasses Market - The smart glasses market is expected to reach 2.46 million units shipped by 2025, with a growth rate of 87.1% [2] - The report notes that while the market is expanding rapidly, there are still challenges in realizing user value and effective market penetration [2] AI Server Industry - The Shenzhen action plan aims for a leap in AI server production and shipment by 2028, focusing on key components like core chips and storage [2] Machine Tool Industry - The machine tool sector is recovering, with a total revenue of 288.7 billion yuan and a 10.3% increase in 2025 [5] - The report indicates a positive trend in exports, which grew by 17.9% to reach 9.68 billion USD [5] Express Delivery Industry - In February 2026, the express delivery sector saw a business volume of approximately 12.11 billion packages, a year-on-year decline of 10.9%, but a 7.1% increase when considering January and February together [7][8] - The report notes that the industry is shifting focus from quantity to quality, with significant price increases observed in the express delivery sector [9]